JP2001522783A - 経口ワクチンおよび治療剤を全身にデリバリーするための組成物および方法 - Google Patents

経口ワクチンおよび治療剤を全身にデリバリーするための組成物および方法

Info

Publication number
JP2001522783A
JP2001522783A JP2000516701A JP2000516701A JP2001522783A JP 2001522783 A JP2001522783 A JP 2001522783A JP 2000516701 A JP2000516701 A JP 2000516701A JP 2000516701 A JP2000516701 A JP 2000516701A JP 2001522783 A JP2001522783 A JP 2001522783A
Authority
JP
Japan
Prior art keywords
botulinum toxin
modified
toxin
modified botulinum
holotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000516701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001522783A5 (enExample
Inventor
ランス・シンプソン
ニキータ・キヤトキン
アンドリュー・マクシモウィッチ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of JP2001522783A publication Critical patent/JP2001522783A/ja
Publication of JP2001522783A5 publication Critical patent/JP2001522783A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2000516701A 1997-10-20 1998-10-16 経口ワクチンおよび治療剤を全身にデリバリーするための組成物および方法 Pending JP2001522783A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/954,302 US6051239A (en) 1997-10-20 1997-10-20 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
US08/954,302 1997-10-20
PCT/US1998/021897 WO1999020306A1 (en) 1997-10-20 1998-10-16 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents

Publications (2)

Publication Number Publication Date
JP2001522783A true JP2001522783A (ja) 2001-11-20
JP2001522783A5 JP2001522783A5 (enExample) 2006-02-16

Family

ID=25495232

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000516701A Pending JP2001522783A (ja) 1997-10-20 1998-10-16 経口ワクチンおよび治療剤を全身にデリバリーするための組成物および方法

Country Status (16)

Country Link
US (1) US6051239A (enExample)
EP (1) EP1024827B1 (enExample)
JP (1) JP2001522783A (enExample)
KR (1) KR100594787B1 (enExample)
CN (1) CN1246038C (enExample)
AT (1) ATE355076T1 (enExample)
AU (1) AU756475B2 (enExample)
BR (1) BR9815255A (enExample)
CA (1) CA2306995A1 (enExample)
DE (1) DE69837209T2 (enExample)
EE (1) EE200000536A (enExample)
HU (1) HUP0101017A3 (enExample)
IL (1) IL135743A (enExample)
NZ (1) NZ504549A (enExample)
RU (1) RU2227042C2 (enExample)
WO (1) WO1999020306A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508121A (ja) * 2002-11-05 2006-03-09 アラーガン、インコーポレイテッド 経口投与用のボツリヌス毒素製剤

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227010B2 (en) 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
KR100753765B1 (ko) * 2000-02-08 2007-08-31 알레간 인코포레이티드 보툴리눔 독소 약제학적 조성물
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
AU2002228887B2 (en) * 2000-11-06 2006-08-24 United States Army Medical Research And Material Command Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
AU2003237346A1 (en) * 2002-05-31 2003-12-19 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
EP1629090B1 (en) * 2002-11-06 2014-03-05 iBio, Inc. Expression of foreign sequences in plants using trans-activation system
US7491509B2 (en) 2003-02-03 2009-02-17 Fraunhofer Usa, Inc. System for expression of genes in plants
US7683238B2 (en) * 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
AU2003300666A1 (en) * 2002-12-20 2004-07-29 Botulinum Toxin Research Associates, Inc. Pharmaceutical botulinum toxin compositions
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
AU2005216133A1 (en) * 2004-02-20 2005-09-09 Fraunhofer Usa, Inc. Systems and methods for clonal expression in plants
US7306807B2 (en) 2004-09-13 2007-12-11 Wyeth Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
US7785606B2 (en) * 2004-11-22 2010-08-31 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
JP4667507B2 (ja) 2005-10-07 2011-04-13 ファイザー・プロダクツ・インク イヌインフルエンザを治療するワクチンおよび方法
EP1931379B1 (en) 2005-10-07 2013-05-29 Health Protection Agency Proteins with improved solubility and methods for producing and using same
US20080299149A1 (en) * 2007-05-30 2008-12-04 Wyeth Raccoon Poxvirus Expressing Genes of Feline Antigens
US8445650B2 (en) * 2007-09-25 2013-05-21 Thomas Jefferson University Mutant botulinum neurotoxin serotype A polypeptide and uses thereof
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
EP2948174B1 (en) 2013-01-28 2019-09-11 New York University Treatment methods using atoxic neurotoxin derivatives
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
EP3230457B1 (en) 2014-12-09 2021-06-30 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
BR112020012641A2 (pt) 2017-12-20 2020-12-01 Allergan, Inc. polipeptídeos de domínio de ligação celular de toxina de botulinum e métodos de uso para rejuvenescimento da pele

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
AU695623B2 (en) * 1994-05-31 1998-08-20 Allergan, Inc. Modification of clostridial toxins for use as transport proteins
EP0796326A4 (en) * 1994-10-24 2000-01-19 Ophidian Pharm Inc VACCINE AND ANTITOXIN FOR THE TREATMENT AND PREVENTION OF C. DIFFICILE DISEASE
WO1996040229A1 (en) * 1995-06-07 1996-12-19 Thomas Jefferson University Vaccines synthesized by transgenic plants
WO1997032599A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508121A (ja) * 2002-11-05 2006-03-09 アラーガン、インコーポレイテッド 経口投与用のボツリヌス毒素製剤

Also Published As

Publication number Publication date
DE69837209T2 (de) 2007-10-31
HUP0101017A3 (en) 2003-11-28
HUP0101017A2 (hu) 2001-07-30
EP1024827B1 (en) 2007-02-28
IL135743A (en) 2004-03-28
CN1290174A (zh) 2001-04-04
WO1999020306A1 (en) 1999-04-29
BR9815255A (pt) 2001-12-26
DE69837209D1 (de) 2007-04-12
US6051239A (en) 2000-04-18
EP1024827A4 (en) 2002-08-28
EE200000536A (et) 2002-04-15
IL135743A0 (en) 2001-05-20
ATE355076T1 (de) 2006-03-15
EP1024827A1 (en) 2000-08-09
AU756475B2 (en) 2003-01-16
CN1246038C (zh) 2006-03-22
RU2227042C2 (ru) 2004-04-20
CA2306995A1 (en) 1999-04-29
KR20010031236A (ko) 2001-04-16
NZ504549A (en) 2002-12-20
KR100594787B1 (ko) 2006-07-03
AU1094799A (en) 1999-05-10

Similar Documents

Publication Publication Date Title
JP2001522783A (ja) 経口ワクチンおよび治療剤を全身にデリバリーするための組成物および方法
Kiyatkin et al. Induction of an immune response by oral administration of recombinant botulinum toxin
JP3927233B2 (ja) 肺炎双球菌感染症に対する免疫化のための肺炎双球菌多糖−組み換えニューモリシン結合体ワクチン類
AU2005287502B2 (en) Immunogenic composition for use in vaccination against staphylococcei
US7727538B2 (en) Methods and compounds for the treatment of mucus hypersecretion
JP5232021B2 (ja) Ｐｅｇ化変異クロストリジウム・ボツリヌム毒素
US7081529B2 (en) Recombinant vaccine against botulinum neurotoxin
JP3370672B2 (ja) ウェルシュ菌ワクチン
CN100513548C (zh) 将AcmA型蛋白质锚融合体与微生物细胞壁材料进行结合的改良方法
US8187585B2 (en) Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
KR100822006B1 (ko) 경구적으로 투여가능한 약제의 전파체로서 작용하는단백질 복합체
JP2005512523A (ja) 炭疽菌抗原性組成物
ES2282992T3 (es) Vacuna para cepa de haemophilus influenzae no tipificable.
US12194090B2 (en) Tetanus vaccine platform for embedding COVID-19 vaccine
JP2790333B2 (ja) 外来プロモーターおよび／またはリーダーペプチドを用いたコレラトキシンｂサブユニットの組換え発現系
MXPA00003799A (en) Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
CZ20001399A3 (cs) Prostředky a způsoby pro systémové podání orálních vakcín a terapeutických činidel
MXPA01003571A (en) Protective recombinant haemophilus influenzae

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090721